| Property | Value |
|---|
|
?:abstract
|
-
Presently, an emerging disease (COVID-19) has been spreading across the world due to coronavirus (SARS-CoV2) For treatment of SARS-CoV2 infection, currently hydroxychloroquine has been suggested by researchers, but it has not been found enough effective against this virus The present study based on in silico approaches was designed to enhance the therapeutic activities of hydroxychloroquine by using curcumin as an adjunct drug against SARS-CoV2 receptor proteins: main-protease and S1 receptor binding domain (RBD) The webserver (ANCHOR) showed the higher protein stability for both receptors with disordered score ( 0 5) The molecular docking analysis revealed that the binding energy (-24 58 kcal/mol) of hydroxychloroquine was higher than curcumin (-20 47 kcal/mol) for receptor main-protease, whereas binding energy of curcumin ( a -38 84 /a kcal/mol) had greater than hydroxychloroquine a (-35 87 /a kcal/mol) in case of S1 receptor binding domain Therefore, this study suggested that the curcumin could be used as combination therapy along with hydroxychloroquine for disrupting the stability of SARS-CoV2 receptor proteins
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
Destabilizing the Structural Integrity of SARS-CoV2 Receptor Proteins by Curcumin Along with Hydroxychloroquine: An Insilco Approach for a Combination Therapy
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}